Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban in percutaneous coronary intervention
NCT01245725Phase 3Withdrawn
- Sponsor
- Medicure Inc.
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina comparing Tirofiban Arm with Placebo Arm (2 arms). Primary endpoint: A composite incidence of death, myocardial infarction and urgent target vessel revascularization at 48 hours. Status: withdrawn.
02
Drugs
tirofiban
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on NCT01245725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245725.